The National Comprehensive Cancer Network released updated guidelines for the treatment of basal cell skin cancer, squamous cell skin cancer, and merkel cell carcinoma.
The Centers for Medicare and Medicaid Services are being urged to make changes that could improve savings for patients and health care payers, as well as expand patient access to biosimilars.
A recent study has shown that patients with relapsed or refractory chronic lymphocytic leukemia may prolong their progression-free survival after treatment with a specific combination regimen.
An adjuvant combination regimen may improve the rate of relapse-free survival by 19% in patients with stage III BRAF-mutated melanoma.
Patients with hepatocellular carcinoma who took a reduced therapy dose had a lower cumulative pill cost and were less likely to discontinue treatment due to toxicities.
Following a recent literature review, a team of researchers have proposed new guidelines for the systematic management of side effects associated with CAR-T cell treatment.
A recent analysis examined the potential correlation between preexisting cardiovascular conditions and risk of heart failure in survivors of non-Hodgkin lymphoma.
Previously-treated patients with stage IV NSCLC are less likely to utilize palliative care or hospice services compared with those who receive no prior oncologic treatment.
A recent study examined whether inpatient palliative care during hematopoietic stem-cell transplant leads to long-term improvements in quality of life and symptom burden for patients.
A patient-driven titration regimen demonstrated better HbA1C control without increasing the risk of hypoglycemia than a physician-driven titration regimen in patients with type 2 diabetes.